Last Price
41.26
Today's Change
-2.45 (5.60%)
Day's Change
41.23 - 45.00
Trading Volume
868,184
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. David Alan Campbell Ph.D. Dr. David Alan Campbell Ph.D.
Full Time Employees: 69 69
IPO Date: 2021-06-11 2021-06-11
CIK: 0001817713 0001817713
ISIN: US47103J1051 US47103J1051
CUSIP: 47103J105 47103J105
Beta: 3.57 3.57
Last Dividend: 0.00 0.00
Dcf Diff: 42.42 42.42
Dcf: -1.16 -1.16
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.